The introduction of novel targeted therapy in CLL has been revolutionary, particularly benefitting ultra-high-risk patients such as those with relapsed/refractory (r/r) disease and TP53 disruption. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.